Aberdeen Group plc Acquires Shares of 90,883 Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Key Points

• Aberdeen Group plc has acquired a new stake in Centessa Pharmaceuticals, purchasing 90,883 shares valued at approximately $1.31 million, reflecting an ownership of 0.07% as per its recent SEC filing.
• Several other institutional investors have increased their stakes in Centessa Pharmaceuticals, with notable increases from Price T Rowe Associates and Adage Capital Partners, contributing to institutional ownership of 82.01% of the company's stock.
• Despite a consensus rating of "Buy" from eleven equity research analysts, Centessa Pharmaceuticals reported a quarterly earnings miss, with an earnings per share of ($0.38), falling short of expectations of ($0.35).

Aberdeen Group plc purchased a new stake in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 90,883 shares of the company's stock, valued at approximately $1,307,000. Aberdeen Group plc owned approximately 0.07% of Centessa Pharmaceuticals as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its holdings in shares of Centessa Pharmaceuticals by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 57,257 shares of the company's stock worth $959,000 after buying an additional 660 shares in the last quarter. Legal & General Group Plc acquired a new position in shares of Centessa Pharmaceuticals in the 4th quarter worth approximately $1,263,000. Barclays PLC raised its holdings in shares of Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after buying an additional 4,952 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Centessa Pharmaceuticals by 14.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company's stock worth $89,854,000 after buying an additional 685,371 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its holdings in shares of Centessa Pharmaceuticals by 22.0% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company's stock worth $85,744,000 after buying an additional 924,027 shares in the last quarter. Institutional investors and hedge funds own 82.01% of the company's stock.

Insider Activity at Centessa Pharmaceuticals

In other news, insider Mario Alberto Accardi sold 8,322 shares of the stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $15.23, for a total transaction of $126,744.06. Following the sale, the insider directly owned 208,163 shares of the company's stock, valued at $3,170,322.49. This represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of the firm's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $17.23, for a total transaction of $103,380.00. Following the completion of the transaction, the general counsel directly owned 105,386 shares in the company, valued at approximately $1,815,800.78. The trade was a 5.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 171,322 shares of company stock valued at $2,472,814 over the last three months. 7.09% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on CNTA. Needham & Company LLC began coverage on Centessa Pharmaceuticals in a report on Wednesday, May 28th. They issued a "buy" rating and a $35.00 target price for the company. Wall Street Zen cut Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, August 16th. Chardan Capital reissued a "buy" rating and issued a $30.00 target price on shares of Centessa Pharmaceuticals in a report on Tuesday, August 12th. Truist Financial assumed coverage on Centessa Pharmaceuticals in a report on Monday, July 21st. They set a "buy" rating and a $30.00 price target for the company. Finally, Oppenheimer started coverage on Centessa Pharmaceuticals in a research note on Thursday, May 8th. They issued an "outperform" rating and a $6.00 price objective on the stock. Eleven equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $28.10.

Centessa Pharmaceuticals Price Performance

Shares of CNTA traded down $0.14 during mid-day trading on Wednesday, hitting $16.65. 960,995 shares of the company traded hands, compared to its average volume of 1,233,414. Centessa Pharmaceuticals PLC Sponsored ADR has a one year low of $9.60 and a one year high of $19.09. The company has a current ratio of 10.11, a quick ratio of 10.12 and a debt-to-equity ratio of 0.32. The business has a 50-day moving average of $15.53 and a 200 day moving average of $14.50. The stock has a market capitalization of $2.23 billion, a price-to-earnings ratio of -9.30 and a beta of 1.48.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.03). As a group, equities analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.